$TVTX
Travere Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000143853321000016 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $47.41M $47.77M
YoY Change -0.76% 20.72%
Cost Of Revenue $1.645M $1.370M
YoY Change 20.07% 34.71%
Gross Profit $45.76M $46.40M
YoY Change -1.37% 20.35%
Gross Profit Margin 96.53% 97.13%
Selling, General & Admin $36.78M $33.14M
YoY Change 10.98% 1.44%
% of Gross Profit 80.37% 71.42%
Research & Development $47.95M $30.25M
YoY Change 58.5% -9.55%
% of Gross Profit 104.77% 65.19%
Depreciation & Amortization $6.074M $5.656M
YoY Change 7.39% 15.41%
% of Gross Profit 13.27% 12.19%
Operating Expenses $84.72M $62.84M
YoY Change 34.83% -19.23%
Operating Profit -$47.55M -$15.07M
YoY Change 215.58% -60.59%
Interest Expense -$5.321M -$4.887M
YoY Change 8.88% 0.45%
% of Operating Profit
Other Income/Expense, Net -$6.005M -$3.101M
YoY Change 93.65% 32.07%
Pretax Income -$53.55M -$18.17M
YoY Change 194.77% -55.22%
Income Tax $300.0K -$19.00M
% Of Pretax Income
Net Earnings -$53.87M $808.0K
YoY Change -6766.71% -101.97%
Net Earnings / Revenue -113.63% 1.69%
Basic Earnings Per Share -$0.96 $0.02
Diluted Earnings Per Share -$0.96 $0.02
COMMON SHARES
Basic Shares Outstanding 56.27M shares 43.12M shares
Diluted Shares Outstanding 56.27M shares 43.59M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $431.0M $269.9M
YoY Change 59.71% -0.3%
Cash & Equivalents $148.2M $67.02M
Short-Term Investments $282.8M $202.8M
Other Short-Term Assets $6.700M $5.300M
YoY Change 26.42% -44.79%
Inventory $7.183M $6.593M
Prepaid Expenses
Receivables $13.10M $18.10M
Other Receivables $17.10M $20.20M
Total Short-Term Assets $565.0M $406.6M
YoY Change 38.96% -14.49%
LONG-TERM ASSETS
Property, Plant & Equipment $11.70M $2.617M
YoY Change 346.96% -12.62%
Goodwill $936.0K $936.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $35.03M $6.803M
YoY Change 414.92% -49.5%
Total Long-Term Assets $199.0M $166.4M
YoY Change 19.57% -13.39%
TOTAL ASSETS
Total Short-Term Assets $565.0M $406.6M
Total Long-Term Assets $199.0M $166.4M
Total Assets $764.0M $573.1M
YoY Change 33.33% -14.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.01M $9.966M
YoY Change 50.59% 30.67%
Accrued Expenses $46.47M $41.59M
YoY Change 11.73% -10.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.01M $68.09M
YoY Change 24.85% -34.58%
LONG-TERM LIABILITIES
Long-Term Debt $218.1M $207.4M
YoY Change 5.16% 5.01%
Other Long-Term Liabilities $43.17M $13.31M
YoY Change 224.27% -43.14%
Total Long-Term Liabilities $43.17M $13.31M
YoY Change 224.27% -43.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.01M $68.09M
Total Long-Term Liabilities $43.17M $13.31M
Total Liabilities $401.4M $347.3M
YoY Change 15.56% -9.07%
SHAREHOLDERS EQUITY
Retained Earnings -$639.7M -$415.6M
YoY Change 53.92% 33.65%
Common Stock $1.003B $642.9M
YoY Change 55.97% 7.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $362.7M $225.7M
YoY Change
Total Liabilities & Shareholders Equity $764.0M $573.1M
YoY Change 33.33% -14.17%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$53.87M $808.0K
YoY Change -6766.71% -101.97%
Depreciation, Depletion And Amortization $6.074M $5.656M
YoY Change 7.39% 15.41%
Cash From Operating Activities -$26.47M -$29.16M
YoY Change -9.2% 42.28%
INVESTING ACTIVITIES
Capital Expenditures $4.495M $208.0K
YoY Change 2061.06% 994.74%
Acquisitions
YoY Change
Other Investing Activities -$96.44M $44.17M
YoY Change -318.34% -694.48%
Cash From Investing Activities -$105.7M $39.55M
YoY Change -367.27% -446.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $195.8M -$5.773M
YoY Change -3490.84% 420.09%
NET CHANGE
Cash From Operating Activities -$26.47M -$29.16M
Cash From Investing Activities -$105.7M $39.55M
Cash From Financing Activities $195.8M -$5.773M
Net Change In Cash $63.46M $4.583M
YoY Change 1284.68% -113.87%
FREE CASH FLOW
Cash From Operating Activities -$26.47M -$29.16M
Capital Expenditures $4.495M $208.0K
Free Cash Flow -$30.97M -$29.36M
YoY Change 5.47% 43.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001438533
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
12200000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2021Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesCurrent
CY2021Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-36257
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
TRAVERE THERAPEUTICS, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4842691
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3611 Valley Centre Drive
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2021Q1 dei City Area Code
CityAreaCode
888
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
969-7879
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
TVTX
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60457654 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
148232000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84772000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
372396000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
276111000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
372639000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276817000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13066000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15925000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
7183000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7608000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6747000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8143000 USD
CY2021Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
17173000 USD
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
17142000 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
565040000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
410407000 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11697000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9418000 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
35030000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33489000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
151342000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
153189000 USD
CY2021Q1 us-gaap Goodwill
Goodwill
936000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
936000 USD
CY2021Q1 us-gaap Assets
Assets
764045000 USD
CY2020Q4 us-gaap Assets
Assets
607439000 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
15008000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12133000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46467000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56793000 USD
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7338000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6334000 USD
CY2021Q1 tvtx Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
16200000 USD
CY2020Q4 tvtx Acquisition Related Contingent Consideration
AcquisitionRelatedContingentConsideration
17400000 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
85013000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
92660000 USD
CY2021Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
218076000 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
215339000 USD
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43167000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40527000 USD
CY2021Q1 tvtx Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
55100000 USD
CY2020Q4 tvtx Acquisition Related Contingent Consideration Noncurrent
AcquisitionRelatedContingentConsiderationNoncurrent
47700000 USD
CY2021Q1 us-gaap Liabilities
Liabilities
401356000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
396226000 USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60435730 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60435730 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52248431 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52248431 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
6000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1002687000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
797985000 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-639742000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585875000 USD
CY2021Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-262000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-902000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
362689000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
211213000 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
764045000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
607439000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47407000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47769000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1645000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1370000 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47946000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30249000 USD
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36778000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33139000 USD
CY2021Q1 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
8587000 USD
CY2020Q1 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
-1922000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
94956000 USD
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
62836000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-47549000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-15067000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1093000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000 USD
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
409000 USD
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1976000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5321000 USD
CY2020Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4887000 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6005000 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3101000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53554000 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18168000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
313000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18976000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56268508 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43122897 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56268508 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43592499 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1103000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
191000 USD
CY2021Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-463000 USD
CY2020Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-2417000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53227000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1418000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6074000 USD
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5656000 USD
CY2021Q1 tvtx Noncash Interest Expense
NoncashInterestExpense
439000 USD
CY2020Q1 tvtx Noncash Interest Expense
NoncashInterestExpense
517000 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-177000 USD
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-138000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2737000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2551000 USD
CY2021Q1 tvtx Provision Benefit For Inventory
ProvisionBenefitForInventory
487000 USD
CY2020Q1 tvtx Provision Benefit For Inventory
ProvisionBenefitForInventory
420000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7694000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5910000 USD
CY2021Q1 tvtx Employee Stock Purchase Plan Expense
EmployeeStockPurchasePlanExpense
214000 USD
CY2020Q1 tvtx Employee Stock Purchase Plan Expense
EmployeeStockPurchasePlanExpense
0 USD
CY2021Q1 tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
8587000 USD
CY2020Q1 tvtx Net Changein Fair Valueof Contingent Consideration
NetChangeinFairValueofContingentConsideration
-1922000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1825000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-6971000 USD
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-788000 USD
CY2020Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2021Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-375000 USD
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
25000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2851000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
61000 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
63000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
958000 USD
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-238000 USD
CY2020Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
18788000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
726000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-7666000 USD
CY2021Q1 tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
3766000 USD
CY2020Q1 tvtx Change In Lease Assets And Liabilities Net
ChangeInLeaseAssetsAndLiabilitiesNet
0 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4443000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-16577000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
23000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-7519000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26474000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29155000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4495000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
208000 USD
CY2021Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4775000 USD
CY2020Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
4406000 USD
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
152399000 USD
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
49153000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
248835000 USD
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
4988000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-105706000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39551000 USD
CY2021Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
732000 USD
CY2020Q1 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5308000 USD
CY2021Q1 tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
525000 USD
CY2020Q1 tvtx Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
525000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2755000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
195753000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5773000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-113000 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-40000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
63460000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4583000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84772000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62436000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148232000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
67019000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
211213000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
221196000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7479000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5714000 USD
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
2755000 USD
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
60000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
12200000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
194255000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-463000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2417000 USD
CY2021Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
1103000 USD
CY2020Q1 us-gaap Temporary Equity Foreign Currency Translation Adjustments
TemporaryEquityForeignCurrencyTranslationAdjustments
191000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
196000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
362689000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
225748000 USD
CY2021Q1 us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The ongoing novel coronavirus (COVID-19) pandemic has resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the three months ended March 31, 2021, these governmental actions and the widespread economic disruption arising from the pandemic have the potential to materially impact our business and influence our business decisions. The extent and duration of the pandemic is unknown, and the future effects on our business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> also known as RE-021, is an investigational product candidate with a dual mechanism of action, selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A, and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Focal segmental glomerulosclerosis ("FSGS")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#4c4c4c;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:15.42pt">Immunoglobulin A nephropathy ("IgAN")</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pe</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">gtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Classical HCU is a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to vision, skeletal, circulatory and central nervous system issues. P</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">egtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) is currently being tested in a Phase 1/2 double blind, randomized, placebo-controlled dose escalation study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. P</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">egtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) has been granted Rare Pediatric Disease and Fast Track designations by the FDA, as well as orphan drug designation in the United States and Europe. We acquired </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TVT-058) as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. CTX is a rare, progressive and underdiagnosed bile acid synthesis disorder affecting many parts of the body. In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in two Cooperative Research and Development Agreements ("CRADAs"), which form a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. We have partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, CDG Care and Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved products:</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. </span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:15.42pt">Cholbam® (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47407000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
47769000 USD
CY2021Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
152400000 USD
CY2021Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
248800000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
372639000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276817000 USD
CY2021Q1 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
282430000 USD
CY2021Q1 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
392000 USD
CY2021Q1 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
45000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
282777000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
372396000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
392000 USD
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
149000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
372639000 USD
CY2020Q4 tvtx Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
271098000 USD
CY2020Q4 tvtx Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
724000 USD
CY2020Q4 tvtx Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
22000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
271800000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
276111000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
728000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276817000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
219346000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
149000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
219346000 USD
CY2021Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
149000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
155174000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
22000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
155174000 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
22000 USD
CY2021Q1 tvtx Number Of Operating Leases
NumberOfOperatingLeases
1 numberOfLeases
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
34600000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
34500000 USD
CY2020Q2 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
7900000 USD
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q1 tvtx Lessee Operating Lease Aggregate Liability
LesseeOperatingLeaseAggregateLiability
49500000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1842000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6020000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6200000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6386000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6578000 USD
CY2021Q1 tvtx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
18535000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
45561000 USD
CY2021Q1 us-gaap Lease Incentive Receivable
LeaseIncentiveReceivable
3247000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10016000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
32298000 USD
CY2021Q1 tvtx Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
4050000 USD
CY2021Q1 tvtx Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
3210000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25038000 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25000000.0 USD
CY2021Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
281900000 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1092000 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
31206000 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
32298000 USD
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 USD
CY2020Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 USD
CY2021Q1 us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
2 business
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
148232000 USD
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
372639000 USD
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
520871000 USD
CY2021Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
71300000 USD
CY2021Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
71300000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84772000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
276817000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
361589000 USD
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
65100000 USD
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
65100000 USD
CY2021Q1 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
8600000 USD
CY2020Q1 tvtx Changein Fair Valueof Contingent Consideration
ChangeinFairValueofContingentConsideration
-1900000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
151300000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
268518000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
264676000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
117176000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
111487000 USD
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
151342000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
153189000 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5952000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5174000 USD
CY2021Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
281900000 USD
CY2021Q1 tvtx Government Rebates Payable
GovernmentRebatesPayable
7912000 USD
CY2020Q4 tvtx Government Rebates Payable
GovernmentRebatesPayable
10707000 USD
CY2021Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
9927000 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
17912000 USD
CY2021Q1 tvtx Accrued Royaltyand Contingent Consideration
AccruedRoyaltyandContingentConsideration
7197000 USD
CY2020Q4 tvtx Accrued Royaltyand Contingent Consideration
AccruedRoyaltyandContingentConsideration
7857000 USD
CY2021Q1 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
12355000 USD
CY2020Q4 tvtx Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
10166000 USD
CY2021Q1 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
4094000 USD
CY2020Q4 tvtx Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
3944000 USD
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56268508 shares
CY2021Q1 tvtx Dilutive Securities Effect On Basic Eps Employee Stock Purchase Plan
DilutiveSecuritiesEffectOnBasicEPSEmployeeStockPurchasePlan
shares
CY2020Q1 tvtx Dilutive Securities Effect On Basic Eps Employee Stock Purchase Plan
DilutiveSecuritiesEffectOnBasicEPSEmployeeStockPurchasePlan
16636 shares
CY2021Q1 tvtx Dilutive Securities Effect On Basic Eps Restricted Stock
DilutiveSecuritiesEffectOnBasicEPSRestrictedStock
shares
CY2020Q1 tvtx Dilutive Securities Effect On Basic Eps Restricted Stock
DilutiveSecuritiesEffectOnBasicEPSRestrictedStock
75044 shares
CY2021Q1 tvtx Dilutive Securities Effect On Basic Eps Options
DilutiveSecuritiesEffectOnBasicEPSOptions
shares
CY2020Q1 tvtx Dilutive Securities Effect On Basic Eps Options
DilutiveSecuritiesEffectOnBasicEPSOptions
377922 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2021Q1 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
4982000 USD
CY2020Q4 tvtx Accrued Liabilities Miscellaneous
AccruedLiabilitiesMiscellaneous
6207000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
46467000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56793000 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56268508 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-53867000 USD
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43122897 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.02
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43592499 shares
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
808000 USD
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17979101 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14807564 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5900000 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.31
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7694000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5910000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000000.0 USD
CY2021Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3435000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3219000 USD
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3748000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4389000 USD
CY2021Q1 us-gaap Inventory Net
InventoryNet
7183000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
7608000 USD
CY2021Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3500000 USD
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3600000 USD
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
13100000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15900000 USD

Files In Submission

Name View Source Status
0001438533-21-000016-index-headers.html Edgar Link pending
0001438533-21-000016-index.html Edgar Link pending
0001438533-21-000016.txt Edgar Link pending
0001438533-21-000016-xbrl.zip Edgar Link pending
ex03312021311.htm Edgar Link pending
ex03312021312.htm Edgar Link pending
ex03312021321.htm Edgar Link pending
ex03312021322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tvtx-20210331.htm Edgar Link pending
tvtx-20210331.xsd Edgar Link pending
tvtx-20210331_cal.xml Edgar Link unprocessable
tvtx-20210331_def.xml Edgar Link unprocessable
tvtx-20210331_g1.gif Edgar Link pending
tvtx-20210331_htm.xml Edgar Link completed
tvtx-20210331_lab.xml Edgar Link unprocessable
tvtx-20210331_pre.xml Edgar Link unprocessable